fbpx

News

Lundbeckfonden Ventures News

Oxford Early Results with CERAMENTT’G show no recurrence of infection, no toxicity and no renal complications.. No late wound leakage and 78 % of patients showing complete bone ingrowth at 6 months. Lund, Sweden, (PRNEWSWIRE) April 15, 2014 – BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation...
MYDICAR is First Gene Therapy Reported to Receive Breakthrough Designation From FDA's Center for Biologics Evaluation and Research (CBER)
Boston, MA – scPharmaceuticals LLC today announced that it has entered into a strategic partnership and product development agreement with Sensile Medical Holding AG of Zug, Switzerland to develop an innovative new therapeutic option for patients with heart failure.  The terms of the agreement were not disclosed. The drug-device combination uses the Sensile SenseCore technology in...
Conference Call Today at 4:30 p.m. Eastern TimeSAN DIEGO, March 31, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced financial results for the quarter and year ended December 31, 2013. "Celladon executed on key...
SAN DIEGO, April 1, 2014 (GLOBE NEWSWIRE) — Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that effective as of the close of the market on Monday, March 31, 2014, the Company was added to the Russell 2000®...
Celladon to Present at BioCentury's Future Leaders in the Biotech Industry ConferenceSAN DIEGO, March 20, 2014 (GLOBE NEWSWIRE) — Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that Krisztina Zsebo, Ph.D., President and Chief Executive Officer, will present...
LUND, Sweden, March 12, 2014 /PRNewswire/ — BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, together with the University of Mainz in Germany, announced that the protocol for the CERAMENTT’Tibia Fracture Study (CERTiFy) was recently published in TRIALS, an open access, peer reviewed...
Lund, Sweden, (PRNEWSWIRE) March 12, 2014 – BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced today that a new drilling performance capability for CERAMENTT’BONE VOID FILLER is now reflected in the product’s Instructions for Use (IFU). The new claim allows for safe...
1 45 46 47 48 49 61

Lundbeckfonden Ventures

Nyheder

BONESUPPORTTM CERTiFy STUDY ON CERAMENT ® BONE VOID FILLER NOW PUBLISHED IN THE JOURNAL OF BONE AND JOINT SURGERY
9. December 2019
Veloxis to Host Conference Call Following Asahi Kasei Group’s Announcement of a Recommended Conditional Voluntary Public Offer for Veloxis
25. November 2019
Asahi Kasei Group Announces a Recommended Conditional Voluntary Public Offer for Veloxis
25. November 2019